Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy
Open Access
- 27 April 2016
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 14 (1) , 1-12
Abstract
Trimetazidine, as an anti-ischemic and antioxidant agent, has been demonstrated to have many cardioprotective effects. However, whether early administration of trimetazidine has an effect on diabetic cardiomyopathy and the mechanisms underlying the effect have not yet been elucidated. We established a type 2 DCM rat model by high-fat diet and low-dose streptozotocin. Rats were separated into different groups: control, diabetes, and diabetes + trimetazidine (n = 6, each). Cardiac autophagy, cardiac functions, and cardiomyocyte apoptosis were monitored. Rats with type 2 DCM showed severe insulin resistance, left ventricular dysfunction, increased cardiomyocyte apoptosis, and reduced cardiac autophagy. Collagen volume fraction (CVF) and perivascular collagen area/luminal area (PVCA/LA) ratio were significantly higher in the diabetic group than the control group. We found that trimetazidine treatment ameliorated metabolic disturbance and insulin resistance, reduced cardiomyocyte apoptosis, and restored cardiac autophagy. CVF and PVCA/LA ratio were also lower in the diabetes + trimetazidine group than the diabetic group (CVF, 4.75 ± 0.52 % vs. 11.04 ± 1.67 %, p < 0.05; PVCA/LA, 8.37 ± 0.51 vs. 17.97 ± 2.66, p < 0.05). Furthermore, trimetazidine inhibited phosphorylation of ERK and P38 MAPK to reduce myocardial fibrosis. Inhibited phosphorylation of AMPK was restored and the interaction between Bcl-2 and Beclin1 was enhanced in diabetes + trimetazidine group, resulting in the initiation of autophagy and alleviation of apoptosis. Early administration of trimetazidine could ameliorate diabetic cardiomyopathy by inhibiting myocardial fibrosis and cardiomyocyte apoptosis and enhancing autophagy. Therefore, trimetazidine may be a good choice in the prevention of diabetic cardiomyopathy if applied at the early stage of diabetes.Keywords
Funding Information
- The National Natural Science Foundation of China (81070141, 81070192, 81100605, 81270287, 81270352, 81300168)
- The National Basic Research Program of China (2012CB722406)
- The Independent Innovation Foundation of Shandong University (2012JC034)
- cardiovascular exploration research foundation of Chinese Medical Doctor Association (DFCMDA201320)
This publication has 27 references indexed in Scilit:
- Autophagy and mitophagy in diabetic cardiomyopathyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2015
- Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathwaysPharmacology & Therapeutics, 2014
- The metabolic modulator trimetazidine triggers autophagy and counteracts stress‐induced atrophy in skeletal muscle myotubesThe FEBS Journal, 2013
- Predictors and prevention of diabetic cardiomyopathyDiabetes, Metabolic Syndrome and Obesity, 2013
- Trimetazidine Protects against Smoking-Induced Left Ventricular Remodeling via Attenuating Oxidative Stress, Apoptosis, and InflammationPLOS ONE, 2012
- Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase–ROS–CTGF pathwayCardiovascular Research, 2010
- A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart FailureJACC, 2006
- Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failureEuropean Heart Journal, 2006
- Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathyAmerican Heart Journal, 2003
- Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathyEuropean Heart Journal, 2001